Francis L. Coolidge’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Francis L. Coolidge’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$246K	Buy	+7,086	New	+$249K	0.3%	108

Other funds holding XBI

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MSA

Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return

ING Group Amsterdam, Netherlands $20.5B AUM 49.71% 1-Year Est. Return

Francis L. Coolidge's XBI Position: Q2 2013 in Review

Francis L. Coolidge opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2013: 7,086 shares worth $246K. The stake represents 0.3% of the portfolio and ranks #108 among its holdings.

123 funds tracked by Wall St. Rank hold XBI as of Q2 2013.

Francis L. Coolidge held 7,086 shares of State Street SPDR S&P Biotech ETF worth $246K as of Q2 2013.
State Street SPDR S&P Biotech ETF was a new Francis L. Coolidge position in Q2 2013.
State Street SPDR S&P Biotech ETF made up 0.3% of Francis L. Coolidge's portfolio in Q2 2013, its #108 holding.
123 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2013.

Based on Francis L. Coolidge's 13F filing for Q2 2013, filed 7 Aug 2013.